News

Carryn Anderson presents her research on GC4419 at ASCO.
Phase II trial describing the efficacy of GC4419 published by the Journal of Clinical Oncology
Garry Buettner was admitted to the "Wall of Scholarship" for publications exceeding 1000 citations.